The DOI matches its Crossref record; 129 of the 129 references it cites were found in a registry or an index.
KRAS-Mutant non-small cell lung cancer: From biology to therapy
Open accessAbstract
In patients with non-small cell lung cancer (NSCLC), the most frequent oncogene driver mutation in Western countries is Kirsten rat sarcoma viral oncogene homolog (KRAS), and KRAS-mutant NSCLC is associated with smoking. There are various sources of biological heterogeneity of KRAS-mutant NSCLC, including different genotypes that may be associated with specific clinical outcomes, the presence of other co-mutations that exhibit different biological features and drug sensitivity patterns, and mutant allelic content. The efficacy of chemotherapy in patients with KRAS-mutant NSCLC is generally poor and numerous novel therapeutic strategies have been developed. These approaches include targeting KRAS membrane associations, targeting downstream signalling pathways, the use of KRAS synthetic lethality, direct targeting of KRAS, and immunotherapy. Of these, immunotherapy may be one of the most promising treatment approaches for patients with KRAS-mutant NSCLC. Recent data also suggest the potential for distinct efficacy of immunotherapy according to the presence of other co-mutations. In view of the biological heterogeneity of KRAS-mutant NSCLC, treatment will likely need to be individualised and, in future, may require the use of rational combinations of treatment, many of which are currently under investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors
Knight, D. A., Ngiow, S. F., Li, M., Parmenter, T., Mok, S., Cass, A., Haynes, N. M., Kinross, K., Yagita, H., Koya, R. C., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66236 · Cited by 269
RetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Self-citationNivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Dols, M. C., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,675
Comprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
Barbacid, M. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.004023 · Cited by 3,885
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Delmore, J. E., Issa, G. C., Lemieux, M. E., Rahl, P. B., Shi, J., Jacobs, H. M., Kastritis, E., Gilpatrick, T., Paranal, R. M., Qi, J., et al. (2011) · Cell · doi:10.1016/j.cell.2011.08.017 · Cited by 2,813
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M. M., Ciuleanu, T.-E., Badin, F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613493 · Cited by 2,503
Self-citationRAS oncogenes: the first 30 years
Malumbres, M., & Barbacid, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1097 · Cited by 1,902
All ras proteins are polyisoprenylated but only some are palmitoylated
Hancock, J. F., Magee, A. I., Childs, J. E., & Marshall, C. J. (1989) · Cell · doi:10.1016/0092-8674(89)90054-8 · Cited by 1,799
The Ras-RasGAP Complex: Structural Basis for GTPase Activation and Its Loss in Oncogenic Ras Mutants
Scheffzek, K., Ahmadian, M. R., Kabsch, W., Wiesmüller, L., Lautwein, A., Schmitz, F., & Wittinghofer, A. (1997) · Science · doi:10.1126/science.277.5324.333 · Cited by 1,543
Ras oncogenes: split personalities
Karnoub, A. E., & Weinberg, R. A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2438 · Cited by 1,467
Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability
Sears, R., Nuckolls, F., Haura, E., Taya, Y., Tamai, K., & Nevins, J. R. (2000) · Genes & Development · doi:10.1101/gad.836800 · Cited by 1,393
Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y., et al. (2008) · Nature Medicine · doi:10.1038/nm.1890 · Cited by 1,330
Rodriguez-Viciana, P., Warne, P. H., Khwaja, A., Marte, B. M., Pappin, D., Das, P., Waterfield, M. D., Ridley, A., & Downward, J. (1997) · Cell · doi:10.1016/s0092-8674(00)80226-3 · Cited by 1,061
Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane
Leevers, S. J., Paterson, H. F., & Marshall, C. J. (1994) · Nature · doi:10.1038/369411a0 · Cited by 1,011
Activation of Raf as a Result of Recruitment to the Plasma Membrane
Stokoe, D., Macdonald, S. G., Cadwallader, K., Symons, M., & Hancock, J. F. (1994) · Science · doi:10.1126/science.7811320 · Cited by 976
Hellmann, M. D., Rizvi, N. A., Goldman, J. W., Gettinger, S. N., Borghaei, H., Brahmer, J. R., Ready, N. E., Gerber, D. E., Chow, L. Q., Juergens, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30624-6 · Cited by 962
Dong, Z.-Y., Zhong, W.-Z., Zhang, X.-C., Su, J., Xie, Z., Liu, S.-Y., Tu, H.-Y., Chen, H.-J., Sun, Y.-L., Zhou, Q., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2554 · Cited by 959
Frederick, D. T., Piris, A., Cogdill, A. P., Cooper, Z. A., Lezcano, C., Ferrone, C. R., Mitra, D., Boni, A., Newton, L. P., Liu, C., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1630 · Cited by 944
Skoulidis, F., Byers, L. A., Diao, L., Papadimitrakopoulou, V. A., Tong, P., Izzo, J., Behrens, C., Kadara, H., Parra, E. R., Canales, J. R., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1236 · Cited by 936
K- and N-Ras Are Geranylgeranylated in Cells Treated with Farnesyl Protein Transferase Inhibitors
Whyte, D. B., Kirschmeier, P., Hockenberry, T. N., Nunez-Oliva, I., James, L., Catino, J. J., Bishop, W. R., & Pai, J.-K. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.22.14459 · Cited by 884
p21ras is modified by a farnesyl isoprenoid.
Casey, P. J., Solski, P. A., Der, C. J., & Buss, J. E. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.21.8323 · Cited by 856
Singh, A., Greninger, P., Rhodes, D., Koopman, L., Violette, S., Bardeesy, N., & Settleman, J. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.022 · Cited by 841
Yeh, E., Cunningham, M., Arnold, H., Chasse, D., Monteith, T., Ivaldi, G., Hahn, W. C., Stukenberg, P. T., Shenolikar, S., Uchida, T., et al. (2004) · Nature Cell Biology · doi:10.1038/ncb1110 · Cited by 791
Lastwika, K. J., Wilson, W., Li, Q. K., Norris, J., Xu, H., Ghazarian, S. R., Kitagawa, H., Kawabata, S., Taube, J. M., Yao, S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-14-3362 · Cited by 785
Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state
Patricelli, M. P., Janes, M. R., Li, L.-S., Hansen, R., Peters, U., Kessler, L. V., Chen, Y., Kucharski, J. M., Feng, J., Ely, T., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1105 · Cited by 759
Patnaik, A., Rosen, L. S., Tolaney, S. M., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Hilton, J. F., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0095 · Cited by 743
Linardou, H., Dahabreh, I. J., Kanaloupiti, D., Siannis, F., Bafaloukos, D., Kosmidis, P., Papadimitriou, C. A., & Murray, S. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70206-7 · Cited by 739
Ras history: The saga continues
Cox, A. D., & Der, C. J. (2010) · Small GTPases · doi:10.4161/sgtp.1.1.12178 · Cited by 706
Comparative biochemical properties of normal and activated human ras p21 protein
McGrath, J. P., Capon, D. J., Goeddel, D. V., & Levinson, A. D. (1984) · Nature · doi:10.1038/310644a0 · Cited by 699
Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
Lito, P., Solomon, M., Li, L.-S., Hansen, R., & Rosen, N. (2016) · Science · doi:10.1126/science.aad6204 · Cited by 691
Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation
Khosravi-Far, R., Solski, P. A., Clark, G. J., Kinch, M. S., & Der, C. J. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.11.6443 · Cited by 683
Jänne, P. A., Shaw, A. T., Pereira, J. R., Jeannin, G., Vansteenkiste, J., Barrios, C., Franke, F. A., Grinsted, L., Zazulina, V., Smith, P., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70489-8 · Cited by 655
Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
Wilmott, J. S., Long, G. V., Howle, J. R., Haydu, L. E., Sharma, R. N., Thompson, J. F., Kefford, R. F., Hersey, P., & Scolyer, R. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2479 · Cited by 652
Dearden, S., Stevens, J., Wu, Y.-L., & Blowers, D. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt205 · Cited by 646
Jordan, E. J., Kim, H. R., Arcila, M. E., Barron, D., Chakravarty, D., Gao, J., Chang, M. T., Ni, A., Kundra, R., Jonsson, P., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1337 · Cited by 643
Koyama, S., Akbay, E. A., Li, Y. Y., Aref, A. R., Skoulidis, F., Herter-Sprie, G. S., Buczkowski, K. A., Liu, Y., Awad, M. M., Denning, W. L., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1439 · Cited by 640
Dogan, S., Shen, R., Ang, D. C., Johnson, M. L., D'Angelo, S. P., Paik, P. K., Brzostowski, E. B., Riely, G. J., Kris, M. G., Zakowski, M. F., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3265 · Cited by 639
Adaptive Immune Resistance: How Cancer Protects from Immune Attack
Ribas, A. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0563 · Cited by 613
Intrinsic GTPase activity distinguishes normal and oncogenic ras p21 molecules.
Gibbs, J. B., Sigal, I. S., Poe, M., & Scolnick, E. M. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.18.5704 · Cited by 609
Mascaux, C., Iannino, N., Martin, B., Paesmans, M., Berghmans, T., Dusart, M., Haller, A., Lothaire, P., Meert, A.-P., Noel, S., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602258 · Cited by 605
PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
D'Incecco, A., Andreozzi, M., Ludovini, V, Rossi, E., Capodanno, A., Landi, L., Tibaldi, C., Minuti, G., Salvini, J., Coppi, E., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2014.555 · Cited by 593
Binding of Ras to Phosphoinositide 3-Kinase p110α Is Required for Ras- Driven Tumorigenesis in Mice
Gupta, S., Ramjaun, A. R., Haiko, P., Wang, Y., Warne, P. H., Nicke, B., Nye, E., Stamp, G., Alitalo, K., & Downward, J. (2007) · Cell · doi:10.1016/j.cell.2007.03.051 · Cited by 589
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma
Hu-Lieskovan, S., Mok, S., Homet Moreno, B., Tsoi, J., Robert, L., Goedert, L., Pinheiro, E. M., Koya, R. C., Graeber, T. G., Comin-Anduix, B., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4691 · Cited by 563
Ihle, N. T., Byers, L. A., Kim, E. S., Saintigny, P., Lee, J. J., Blumenschein, G. R., Tsao, A., Liu, S., Larsen, J. E., Wang, J., et al. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr523 · Cited by 532
The product of ras is a GTPase and the T24 oncogenic mutant is deficient in this activity
Sweet, R. W., Yokoyama, S., Kamata, T., Feramisco, J. R., Rosenberg, M., & Gross, M. (1984) · Nature · doi:10.1038/311273a0 · Cited by 531
A Genomics-Based Classification of Human Lung Tumors
The Clinical Lung Cancer Genome Project (CLCGP) and Network Genomic Medicine (NGM) (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006802 · Cited by 511
Garassino, M. C., Martelli, O., Broggini, M., Farina, G., Veronese, S., Rulli, E., Bianchi, F., Bettini, A., Longo, F., Moscetti, L., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70310-3 · Cited by 475
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
Chen, Z., Cheng, K., Walton, Z., Wang, Y., Ebi, H., Shimamura, T., Liu, Y., Tupper, T., Ouyang, J., Li, J., et al. (2012) · Nature · doi:10.1038/nature10937 · Cited by 446
Yoshizawa, A., Sumiyoshi, S., Sonobe, M., Kobayashi, M., Fujimoto, M., Kawakami, F., Tsuruyama, T., Travis, W. D., Date, H., & Haga, H. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182769aa8 · Cited by 436
Shimizu, T., Tolcher, A. W., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Smith, L. S., Gunn, S., Smetzer, L., Mays, T. A., Kaiser, B., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2381 · Cited by 431
Puyol, M., Martín, A., Dubus, P., Mulero, F., Pizcueta, P., Khan, G., Guerra, C., Santamaría, D., & Barbacid, M. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.025 · Cited by 415
A combinatorial strategy for treating KRAS-mutant lung cancer
Manchado, E., Weissmueller, S., Morris, J. P., Chen, C.-C., Wullenkord, R., Lujambio, A., de Stanchina, E., Poirier, J. T., Gainor, J. F., Corcoran, R. B., et al. (2016) · Nature · doi:10.1038/nature18600 · Cited by 403
Spranger, S., Luke, J. J., Bao, R., Zha, Y., Hernandez, K. M., Li, Y., Gajewski, A. P., Andrade, J., & Gajewski, T. F. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1609376113 · Cited by 399
Direct Demonstration of Geranylgeranylation and Farnesylation of Ki-Ras in Vivo
Rowell, C. A., Kowalczyk, J. J., Lewis, M. D., & Garcia, A. M. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.22.14093 · Cited by 368
Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?
Cox, A. D., Der, C. J., & Philips, M. R. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3214 · Cited by 351
Blumenschein, G. R., Smit, E. F., Planchard, D., Kim, D.-W., Cadranel, J., De Pas, T., Dunphy, F., Udud, K., Ahn, M.-J., Hanna, N. H., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv072 · Cited by 349
LKB1 loss links serine metabolism to DNA methylation and tumorigenesis
Kottakis, F., Nicolay, B. N., Roumane, A., Karnik, R., Gu, H., Nagle, J. M., Boukhali, M., Hayward, M. C., Li, Y. Y., Chen, T., et al. (2016) · Nature · doi:10.1038/nature20132 · Cited by 348
Wright, L. P., & Philips, M. R. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r600004-jlr200 · Cited by 343
Jänne, P. A., van den Heuvel, M. M., Barlesi, F., Cobo, M., Mazieres, J., Crinò, L., Orlov, S., Blackhall, F., Wolf, J., Garrido, P., et al. (2017) · JAMA · doi:10.1001/jama.2017.3438 · Cited by 335
Mao, C., Qiu, L.-X., Liao, R.-Y., Du, F.-B., Ding, H., Yang, W.-C., Li, J., & Chen, Q. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2009.11.020 · Cited by 313
Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities
Kerr, E. M., Gaude, E., Turrell, F. K., Frezza, C., & Martins, C. P. (2016) · Nature · doi:10.1038/nature16967 · Cited by 313
Blasco, R. B., Francoz, S., Santamaría, D., Cañamero, M., Dubus, P., Charron, J., Baccarini, M., & Barbacid, M. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.002 · Cited by 302
Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice
Soucek, L., Whitfield, J. R., Sodir, N. M., Massó-Vallés, D., Serrano, E., Karnezis, A. N., Swigart, L. B., & Evan, G. I. (2013) · Genes & Development · doi:10.1101/gad.205542.112 · Cited by 301
Shepherd, F. A., Domerg, C., Hainaut, P., Jänne, P. A., Pignon, J.-P., Graziano, S., Douillard, J.-Y., Brambilla, E., Le Chevalier, T., Seymour, L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.1390 · Cited by 293
Activated Ras interacts with the Ral guanine nucleotide dissociation stimulator.
Hofer, F., Fields, S., Schneider, C., & Martin, G. S. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.23.11089 · Cited by 287
Calles, A., Liao, X., Sholl, L. M., Rodig, S. J., Freeman, G. J., Butaney, M., Lydon, C., Dahlberg, S. E., Hodi, F. S., Oxnard, G. R., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000687 · Cited by 271
Sos, M. L., Fischer, S., Ullrich, R., Peifer, M., Heuckmann, J. M., Koker, M., Heynck, S., Stückrath, I., Weiss, J., Fischer, F., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907325106 · Cited by 254
Ral GTPases and cancer: linchpin support of the tumorigenic platform
Bodemann, B. O., & White, M. A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2296 · Cited by 235
KRAS Mutation: Should We Test for It, and Does It Matter?
Roberts, P. J., & Stinchcombe, T. E. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.0454 · Cited by 228
Metabolic Dependencies in RAS-Driven Cancers
Kimmelman, A. C. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2425 · Cited by 224
Adjei, A. A., Mauer, A., Bruzek, L., Marks, R. S., Hillman, S., Geyer, S., Hanson, L. J., Wright, J. J., Erlichman, C., Kaufmann, S. H., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.075 · Cited by 219
Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non–Small Cell Lung Cancer
Shimamura, T., Chen, Z., Soucheray, M., Carretero, J., Kikuchi, E., Tchaicha, J. H., Gao, Y., Cheng, K. A., Cohoon, T. J., Qi, J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3904 · Cited by 202
Kadara, H., Choi, M., Zhang, J., Parra, E. R., Rodriguez-Canales, J., Gaffney, S. G., Zhao, Z., Behrens, C., Fujimoto, J., Chow, C., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw436 · Cited by 200
RAL GTPases are linchpin modulators of human tumour‐cell proliferation and survival
Chien, Y., & White, M. A. (2003) · EMBO reports · doi:10.1038/sj.embor.embor899 · Cited by 193
Papadimitrakopoulou, V., Lee, J. J., Wistuba, I. I., Tsao, A. S., Fossella, F. V., Kalhor, N., Gupta, S., Byers, L. A., Izzo, J. G., Gettinger, S. N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.0084 · Cited by 183
RalGDS is required for tumor formation in a model of skin carcinogenesis
González-García, A., Pritchard, C. A., Paterson, H. F., Mavria, G., Stamp, G., & Marshall, C. J. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.029 · Cited by 181
Spigel, D. R., Schrock, A. B., Fabrizio, D., Frampton, G. M., Sun, J., He, J., Gowen, K., Johnson, M. L., Bauer, T. M., Kalemkerian, G. P., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.9017 · Cited by 177
Ambrogio, C., Gómez-López, G., Falcone, M., Vidal, A., Nadal, E., Crosetto, N., Blasco, R. B., Fernández-Marcos, P. J., Sánchez-Céspedes, M., Ren, X., et al. (2016) · Nature Medicine · doi:10.1038/nm.4041 · Cited by 176
Scheffzek, K., Lautwein, A., Kabsch, W., Reza Ahmadian, M., & Wittinghofer, A. (1996) · Nature · doi:10.1038/384591a0 · Cited by 173
Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas
Johnson, M. L., Sima, C. S., Chaft, J., Paik, P. K., Pao, W., Kris, M. G., Ladanyi, M., & Riely, G. J. (2013) · Cancer · doi:10.1002/cncr.27730 · Cited by 166
RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?
Downward, J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2180 · Cited by 166
Sumimoto, H., Takano, A., Teramoto, K., & Daigo, Y. (2016) · PLOS ONE · doi:10.1371/journal.pone.0166626 · Cited by 165
Hainsworth, J. D., Cebotaru, C. L., Kanarev, V., Ciuleanu, T. E., Damyanov, D., Stella, P., Ganchev, H., Pover, G., Morris, C., & Tzekova, V. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181e8b3a3 · Cited by 162
A Phase II Trial of Salirasib in Patients with Lung Adenocarcinomas with KRAS Mutations
Riely, G. J., Johnson, M. L., Medina, C., Rizvi, N. A., Miller, V. A., Kris, M. G., Pietanza, M. C., Azzoli, C. G., Krug, L. M., Pao, W. J., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318223c099 · Cited by 160
Tolcher, A. W., Patnaik, A., Papadopoulos, K. P., Rasco, D. W., Becerra, C. R., Allred, A. J., Orford, K., Aktan, G., Ferron-Brady, G., Ibrahim, N., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2615-5 · Cited by 158
Ribas, A., Butler, M., Lutzky, J., Lawrence, D. P., Robert, C., Miller, W., Linette, G. P., Ascierto, P. A., Kuzel, T., Algazi, A. P., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.3003 · Cited by 158
KRAS-G12C Mutation Is Associated with Poor Outcome in Surgically Resected Lung Adenocarcinoma
Nadal, E., Chen, G., Prensner, J. R., Shiratsuchi, H., Sam, C., Zhao, L., Kalemkerian, G. P., Brenner, D. E., Lin, J., Reddy, R. M., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000305 · Cited by 149
Prognostic Impact of KRAS Mutation Subtypes in 677 Patients with Metastatic Lung Adenocarcinomas
Yu, H. A., Sima, C. S., Shen, R., Kass, S. L., Gainor, J. F., Shaw, A. T., Hames, M. L., Iams, W. T., Aston, J. L., Lovly, C. M., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000432 · Cited by 148
Monotherapy Administration of Sorafenib in Patients With Non–Small Cell Lung Cancer (MISSION) Trial
Paz-Ares, L. G., Hirsh, V., Zhang, L., de Marinis, F., Yang, J. C., Wakelee, H. A., Seto, T., Wu, Y.-L. L. C., Novello, S., Juhász, É., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000693 · Cited by 129
Self-citationRHOA-FAK is a required signaling axis for the maintenance of KRAS-driven lung adenocarcinomas
Konstantinidou, G., Ramadori, G., Torti, F., Kangasniemi, K., Ramirez, R. E., Cai, Y., Behrens, C., Dellinger, M. T., Brekken, R. A., Wistuba, I. I., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0388 · Cited by 114
Kim, E. S., Kies, M. S., Fossella, F. V., Glisson, B. S., Zaknoen, S. L., Statkevich, P., Munden, R. F., Summey, C., Pisters, K. M. W., Papadimitrakopoulou, V., et al. (2005) · Cancer · doi:10.1002/cncr.21188 · Cited by 106
Marabese, M., Ganzinelli, M., Garassino, M. C., Shepherd, F. A., Piva, S., Caiola, E., Macerelli, M., Bettini, A., Lauricella, C., Floriani, I., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5607 · Cited by 95
Huynh, T. G., Morales‐Oyarvide, V., Campo, M. J., Gainor, J. F., Bozkurtlar, E. B., Uruga, H., Zhao, L. P., Gomez‐Caraballo, M., Hata, A. N., Mark, E. J., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.08.134 · Cited by 92
Carter, C. A., Rajan, A., Keen, C., Szabo, E. M., Khozin, S., Thomas, A., Brzezniak, C. E., Guha, U., Doyle, L. A., Steinberg, S. M., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw008 · Cited by 90
Direct Attack on RAS: Intramolecular Communication and Mutation-Specific Effects
Marcus, K., & Mattos, C. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2148 · Cited by 82
Metabolic rewiring in mutant Kras lung cancer
Kerr, E. M., & Martins, C. P. (2017) · FEBS Journal · doi:10.1111/febs.14125 · Cited by 82
Dingemans, A. C., Mellema, W. W., Groen, H. J. M., van Wijk, A. W., Burgers, S. A., Kunst, P. W. A., Thunnissen, E., Heideman, D. A. M., & Smit, E. F. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1779 · Cited by 78
Janne, P. A., Smith, I. C. P., McWalter, G., Mann, H., Dougherty, B. A., Walker, J., Orr, M. C. M., Hodgson, D., Shaw, A. T., Pereira, J. R., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.215 · Cited by 77
Comprehensive Biomarker Analysis and Final Efficacy Results of Sorafenib in the BATTLE Trial
Blumenschein, G. R., Saintigny, P., Liu, S., Kim, E. S., Tsao, A. S., Herbst, R. S., Alden, C. M., Lee, J. J., Tang, X., Stewart, D. J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1818 · Cited by 64
COSMIC (Catalogue of Somatic Mutations in Cancer)
Griffith, M., & Griffith, O. L. (2004) · Wiley eBooks · doi:10.1002/9780471650126.dob0851 · Cited by 56
Juric, D., Soria, J., Sharma, S., Banerji, U., Azaro, A., Desai, J., Ringeisen, F. P., Kaag, A., Radhakrishnan, R., Hourcade‐Potelleret, F., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.9051 · Cited by 55
Goldman, J. W., Shi, P., Reck, M., Paz-Ares, L. G., Koustenis, A. G., & Hurt, K. C. (2015) · Clinical Lung Cancer · doi:10.1016/j.cllc.2015.08.003 · Cited by 52
Self-citationDoes KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)?
Macerelli, M., Caramella, C., Faivre, L., Besse, B., Planchard, D., Polo, V., Camus, M. N., Celebic, A., Koubi-Pick, V., Lacroix, L., et al. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2013.12.013 · Cited by 52
Biological therapies in nonsmall cell lung cancer
Zugazagoitia, J., Molina‐Pinelo, S., López‐Ríos, F., & Paz-Ares, L. G. (2017) · European Respiratory Journal · doi:10.1183/13993003.01520-2016 · Cited by 52
Self-citationValue of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial
Rulli, E., Marabese, M., Torri, V., Farina, G., Veronese, S. M., Bettini, A., Longo, F., Moscetti, L. I., Ganzinelli, M., Lauricella, C., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv318 · Cited by 47
Ribas, A., Hodi, F. S., Lawrence, D. P., Atkinson, V. G., Starodub, A., Carlino, M. S., Fisher, R. A., Long, G. V., Miller, W. H., Huang, Y., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.3014 · Cited by 47
16th World Conference on Lung Cancer
Nielsen, T. B., Brink, C., Sloth Møller, D., Hoffmann, L., Lutz, C. M., Appelt, A. L., Lund, M. D., Nielsen, M. S., Sibolt, P., Larsen, C., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/01.jto.0000473439.77589.a7 · Cited by 45
Shapiro, G. I., LoRusso, P. M., Kwak, E. L., Cleary, J. M., Musib, L. C., Jones, C. B., de Crespigny, A. J., Belvin, M. P., McKenzie, M., Gates, M. R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.3005 · Cited by 44
Riely, G. J., Brahmer, J. R., Planchard, D., Crinò, L., Doebele, R. C., Lopez, L. A. M., Gettinger, S. N., Schumann, C., Li, X. N., Atkins, B., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.7531 · Cited by 39
Smit, E. F., Dingemans, A. C., Thunnissen, E., Hochstenbach, M., van Suylen, R. J., & Postmus, P. E. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181d86ebf · Cited by 37
Chénard-Poirier, M., Kaiser, M., Boyd, K. D., Sriskandarajah, P., Constantinidou, A., Harris, S. J., Fandos, S. S., Ryan, A. A., Witt, K. D., Dawes, J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.2506 · Cited by 31
KRAS-G12C Mutation is Associated with Poor Outcome in Surgically Resected Lung Adenocarcinoma
Nadal, E., Beer, D. G., & Ramnath, N. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000438 · Cited by 31
Heist, R. S., Gandhi, L., Shapiro, G. I., Rizvi, N. A., Burris, H. A., Bendell, J. C., Baselga, J. M., Yerganian, S. B., Hsu, K., Ogden, J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.2530 · Cited by 28
Goldman, J. W., Mazières, J., Barlési, F., Koczywas, M., Dragnev, K. H., Göksel, T., Cortot, A. B., Girard, N., Wesseler, C., Bischoff, H. G., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.9025 · Cited by 26
Self-citationRedig, A. J., Chambers, E. S., Lydon, C., Dahlberg, S. E., Alden, R. S., & Janne, P. A. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.9087 · Cited by 17
Phase II trial of bortezomib in KRAS G12D mutant lung cancers.
Litvak, A. M., Drilon, A. E. D. C., Rekhtman, N., Pietanza, M. C., Chaft, J. E., Woo, K. M., Paik, P. K., Kris, M. G., & Riely, G. J. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.e19002 · Cited by 16
Ramanathan, R. K., Hoff, D. D. V., Eskens, F. A. L. M., Blumenschein, G. R., Richards, D., Renshaw, F. G., Rajagopalan, P., Kelly, A. T., Peña, C. E., & Mross, K. B. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.2588 · Cited by 16
Riely, G. J., Jordan, E., Kim, H. R., Yu, H. A., Berger, M. F., Solit, D. B., Kris, M. G., Ni, A., Arcila, M. E., & Ladanyi, M. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.9019 · Cited by 14
Lee, M.-H., Yanagawa, J., Li, R., Walser, T. C., Krysan, K., Wang, G., Goldman, J. W., Garon, E. B., Zeng, G., Sharma, S., et al. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-3-s2-p305 · Cited by 10
Cited by
The emerging treatment landscape of targeted therapy in non-small-cell lung cancer
Yuan, M., Huang, L.-L., Chen, J.-H., Wu, J., & Xu, Q. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0099-9 · Cited by 679
Imyanitov, E. N., Iyevleva, A. G., & Levchenko, E. V. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103194 · Cited by 526
Targeted Therapy and Checkpoint Immunotherapy in Lung Cancer
Ruiz-Cordero, R., & Devine, W. P. (2020) · Surgical Pathology Clinics · doi:10.1016/j.path.2019.11.002 · Cited by 448
Yang, Y., Wang, Z., Fang, J., Yu, Q., Han, B., Cang, S., Chen, G., Mei, X., Yang, Z., Ma, R., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.07.014 · Cited by 390
Pennell, N. A., Arcila, M. E., Gandara, D. R., & West, H. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_237863 · Cited by 310
Metadata
- Authors
- Ferrer, I., Zugazagoitia, J., Herbertz, S., John, W., Paz-Ares, L., & Schmid-Bindert, G.
- Venue
- Lung Cancer
- Publisher
- Elsevier BV
- Published
- 2018-10
- Volume
- 124
- Pages
- 53-64
- ISSN
- 0169-5002 (ISSN-L)
- OpenAlex
- W2883160489
- Cited by
- 311
- References
- 129
- FWCI
- 25.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.